2,826 research outputs found

    Magnesium and aluminum sulfates in salt efflorescences from acid mine drainage in the Iberian Pyrite Belt (SW Spain)

    Get PDF
    Proceedings IMWA 2016, Freiberg/Germany | Drebenstedt, Carsten, Paul, Michael (eds.) | Mining Meets Water – Conflicts and Solutions.The current study is focused on AMD-precipitates that compose the typical magnesium and aluminum sulfate assemblages in the Spanish sector of the Iberian Pyrite Belt (SW Spain). The main objectives are identify and describe the composition, morphology and paragenetic relationships of these sulfate phases. From the methodological pint of view, sampling procedure covered the entire metallogenetic province, including five selected representative mines and eight river basins, which are the main receptors of the acid mine drainage discharges. The mineralogical analyses were performed by X-Ray diffraction and electron microscopy. The obtained results showed the extraordinary abundance of aluminum sulfates with acicular habit, from the series pickeringite-apjhonite-halotrichite. They form typical assemblages with other aluminum sulfates, such as alunogen and tamarugite, and with the Mg sulfates: epsomite and hexahydrite. Moreover, the paragenetic relationships indicate the late occurrence of acicular Alsulfates from the halotrichite group.Financial support for this research was provided by the Andalusian Autonomous Government Excellence Project, code P06-RNM-02167. This work was also co-funded by the European Union through the European Regional Development Fund, based on COMPETE 2020 (Programa Operacional da Competitividade e Internacionalização), project ICT (UID/GEO/04683/2013) with reference POCI-01-0145-FEDER-007690 and national funds provided by Fundação para a Ciência e Tecnologia.info:eu-repo/semantics/publishedVersio

    Acceso a jeringas estériles entre los jóvenes de Madrid y Barcelona que se inyectan drogas y su asociación con las prácticas de riesgo

    Get PDF
    [EN] To evaluate access to sterile syringes and its association with injection risk behaviour in Madrid and Barcelona. Cross-sectional community study by computer-assisted personal interview in 465 young heroin injectors between 2001 and 2003. Some 4.2% had not obtained any free sterile syringes in the previous 12 months. In Madrid 32.1% had obtained all their sterile syringes free of charge (ASSF), versus 44.6% in Barcelona (p<0.01). Not sharing (not using syringes used by someone else and not front/backloading) was associated with obtaining ASSF (OR=1.69) and with sporadic injection (OR=1.83). Not reusing one's own syringes was associated with the same two variables (OR=4.02 and OR=2.50, respectively). Access to sterile syringes is very high in Madrid and Barcelona, although the two cities have different approaches. The acquisition of all syringes free of charge should be facilitated, especially among frequent injectors. [ES] Evaluar el acceso a jeringas estériles y su asociación con prácticas de inyección de riesgo en Madrid y Barcelona. Material y método: Estudio transversal en la comunidad de 465 jóvenes que se inyectan heroína, realizado entre 2001 y 2003, mediante entrevista asistida por ordenador. Un 4,2% no obtuvo jeringas estériles gratuitas en los últimos 12 meses. En Madrid, el 32,1% obtuvo todas las jeringas estériles gratis (TJEG), frente al 44,6% de Barcelona (p < 0,01). No compartir (no utilizar jeringas ajenas usadas o droga diluida en las usadas por otros) se asoció con obtener TJEG (odds ratio [OR] = 1,69) e inyectarse esporádicamente (OR = 1,83). No reutilizar las jeringas propias se asoció con las mismas variables (OR = 4,02 y OR = 2,50, respectivamente). En Madrid y Barcelona el acceso a jeringas estériles es muy elevado, aunque con modelos diferentes. Debe facilitarse la obtención de todas las jeringas estériles gratis, especialmente entre los jóvenes que se inyectan con mayor frecuencia.This research was financed primarily by the Fundación para Investigación y la Prevención del Sida en España (FIPSE 3035/99 - Foundation for AIDS Research and Prevention in Spain); the analysis was possible thanks to the support of the Ciber de Epidemiología y Salud Pública.S

    Can the Holmes-Rahe Social Readjustment Rating Scale (SRRS) Be Used as a Suicide Risk Scale? An Exploratory Study

    Get PDF
    The objective of this research was to examine whether the Holmes-Rahe Social Readjustment Rating Scale, a life event scale, can be used to identify suicide attempters. The Holmes-Rahe Social Readjustment Rating Scale\u27s ability to identify suicide attempters was tested in 1183 subjects (478 suicide attempters, 197 psychiatric inpatients, and 508 healthy controls) using the Fisher Linear Discriminant Analysis and traditional psychometric methods. The Fisher Linear Discriminant Analysis outperformed traditional psychometric approaches (area under the curve: 0.85 vs. 0.78; p \u3c 0.05) and indicated that this scale may be used to identify suicide attempters. The life events that better characterized suicide attempters were change in frequency of arguments, marital separation, and personal injury. The Holmes-Rahe Social Readjustment Rating Scale may help identify suicide attempters

    Three dimensional magnetic nanowires grown by focused electron-beam induced deposition

    Get PDF
    Control of the motion of domain walls in magnetic nanowires is at the heart of various recently proposed three-dimensional (3D) memory devices. However, fabricating 3D nanostructures is extremely complicated using standard lithography techniques. Here we show that highly pure 3D magnetic nanowires with aspect-ratios of ~100 can be grown using focused electron-beam-induced-deposition. By combining micromanipulation, Kerr magnetometry and magnetic force microscopy, we determine that the magnetisation reversal of the wires occurs via the nucleation and propagation of domain walls. In addition, we demonstrate that the magnetic switching of individual 3D nanostructures can be directly probed by magneto-optical Kerr effect

    Predictors of Global Non-Motor Symptoms Burden Progression in Parkinson's Disease. Results from the COPPADIS Cohort at 2-Year Follow-Up

    Get PDF
    Malaltia de Parkinson; Símptomes no motors; ProgressióEnfermedad de Parkinson; Sintomas no motores; ProgresiónParkinson’s disease; Non-motor symptoms; ProgressionBackground and Objective: Non-motor symptoms (NMS) progress in different ways between Parkinson’s disease (PD) patients. The aim of the present study was to (1) analyze the change in global NMS burden in a PD cohort after a 2-year follow-up, (2) to compare the changes with a control group, and (3) to identify predictors of global NMS burden progression in the PD group. Material and Methods: PD patients and controls, recruited from 35 centers of Spain from the COPPADIS cohort from January 2016 to November 2017, were followed-up with after 2 years. The Non-Motor Symptoms Scale (NMSS) was administered at baseline (V0) and at 24 months ± 1 month (V2). Linear regression models were used for determining predictive factors of global NMS burden progression (NMSS total score change from V0 to V2 as dependent variable). Results: After the 2-year follow-up, the mean NMS burden (NMSS total score) significantly increased in PD patients by 18.8% (from 45.08 ± 37.62 to 53.55 ± 42.28; p < 0.0001; N = 501; 60.2% males, mean age 62.59 ± 8.91) compared to no change observed in controls (from 14.74 ± 18.72 to 14.65 ± 21.82; p = 0.428; N = 122; 49.5% males, mean age 60.99 ± 8.32) (p < 0.0001). NMSS total score at baseline (β = −0.52), change from V0 to V2 in PDSS (Parkinson’s Disease Sleep Scale) (β = −0.34), and change from V0 to V2 in NPI (Neuropsychiatric Inventory) (β = 0.25) provided the highest contributions to the model (adjusted R-squared 0.41; Durbin-Watson test = 1.865). Conclusions: Global NMS burden demonstrates short-term progression in PD patients but not in controls and identifies worsening sleep problems and neuropsychiatric symptoms as significant independent predictors of this NMS progression.This research was funded by Fundación Española de Ayuda a la Investigación en Parkinson y otras Enfermedades Neuro-degenerativa

    Predictors of clinically significant quality of life impairment in Parkinson’s disease

    Get PDF
    Parkinson's disease; Quality of lifeEnfermedad de Parkinson; Calidad de vidaMalaltia de Parkinson; Qualitat de vidaQuality of life (QOL) plays an important role in independent living in Parkinson’s disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment in PD patients from a Spanish cohort. PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed up during 2 years. Health-related QoL (HRQoL) and global QoL (GQoL) were assessed with the 39-item Parkinson’s disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8), respectively, at baseline (V0) and at 24 months ± 1 month (V2). Clinically significant QoL impairment was defined as presenting an increase (PDQ-39SI) or decrement (EUROHIS-QOL8) at V2 ≥ 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL did not change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 ± 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 ± 13 to 20.3 ± 16.4; p < 0.0001) at V2. Ninety-three patients (18.6%) presented a clinically significant HRQoL impairment at V2. To be younger (OR = 0.896; 95% CI 0.829–0.968; p = 0.006), to be a female (OR = 4.181; 95% CI 1.422–12.290; p = 0.009), and to have a greater increase in BDI-II (Beck Depression Inventory-II) (OR = 1.139; 95% CI 1.053–1.231; p = 0.001) and NMSS (Non-Motor Symptoms Scale) (OR = 1.052; 95% CI 1.027–1.113; p < 0.0001) total scores from V0 to V2 were associated with clinically significant HRQoL impairment at the 2-year follow-up (Hosmer–Lemeshow test, p = 0.665; R 2 = 0.655). An increase in ≥5 and ≥10 points of BDI-II and NMSS total score at V2 multiplied the probability of presenting clinically significant HRQoL impairment by 5 (OR = 5.453; 95% CI 1.663–17.876; p = 0.005) and 8 (OR = 8.217; 95% CI, 2.975–22.696; p = 0.002), respectively. In conclusion, age, gender, mood, and non-motor impairment were associated with clinically significant HRQoL impairment after the 2-year follow-up in PD patients

    Risk of Cognitive Impairment in Patients With Parkinson’s Disease With Visual Hallucinations and Subjective Cognitive Complaints

    Get PDF
    Cognitive impairment; Parkinson's disease; Visual hallucinationsDeterioro cognitivo; Enfermedad de Parkinson; Alucinaciones visualesDeteriorament cognitiu; Malaltia de Parkinson; Al·lucinacions visualsBackground and Purpose Visual hallucinations (VH) and subjective cognitive complaints (SCC) are associated with cognitive impairment (CI) in Parkinson’s disease. Our aims were to determine the association between VH and SCC and the risk of CI development in a cohort of patients with Parkinson’s disease and normal cognition (PD-NC). Methods Patients with PD-NC (total score of >80 on the Parkinson’s Disease Cognitive Rating Scale [PD-CRS]) recruited from the Spanish COPPADIS cohort from January 2016 to November 2017 were followed up after 2 years. Subjects with a score of ≥1 on domain 5 and item 13 of the Non-Motor Symptoms Scale at baseline (V0) were considered as “with SCC” and “with VH,” respectively. CI at the 2-year follow-up (plus or minus 1 month) (V2) was defined as a PD-CRS total score of <81. Results At V0 (n=376, 58.2% males, age 61.14±8.73 years [mean±SD]), the frequencies of VH and SCC were 13.6% and 62.2%, respectively. VH were more frequent in patients with SCC than in those without: 18.8% (44/234) vs 4.9% (7/142), p<0.0001. At V2, 15.2% (57/376) of the patients had developed CI. VH presenting at V0 was associated with a higher risk of CI at V2 (odds ratio [OR]=2.68, 95% confidence interval=1.05–6.83, p=0.0.039) after controlling for the effects of age, disease duration, education, medication, motor and nonmotor status, mood, and PD-CRS total score at V0. Although SCC were not associated with CI at V2, presenting both VH and SCC at V0 increased the probability of having CI at V2 (OR=3.71, 95% confidence interval=1.36–10.17, p=0.011). Conclusions VH were associated with the development of SCC and CI at the 2-year follow-up in patients with PD-NC.The resources obtained for the development of this project have been obtained by the Degen Foundation (https://fundaciondegen.org/). A part of the Project is financed with grants from the Spanish Ministry of Economy and Competitiveness [PI16/01575] co-founded by ISCIII (Concesión de subvenciones de Proyectos de Investigación en Salud de la convocatoria 2020 de la Acción Estratégica en Salud 2017-2020 por el proyecto “PROGRESIÓN NO MOTORA E IMPACTO EN LA CALIDAD DE VIDA EN LA ENFERMEDAD DE PARKINSON”)
    corecore